TOP TEN perturbations for 1033_g_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1033_g_at
Selected probe(set): 207008_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1033_g_at (207008_at) across 6673 perturbations tested by GENEVESTIGATOR:
esophageal adenocarcinoma study 1 / normal esophageal epithelium sample
Relative Expression (log2-ratio):-5.3587303Number of Samples:20 / 18
| Experimental | esophageal adenocarcinoma study 1 |
| Esophageal adenocarcinoma (EAC) samples of affected epithelium recovered by laser capture microdissection technique. | |
| Control | normal esophageal epithelium sample |
| Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy. |
esophageal squamous cell carcinoma study 1 / normal esophageal epithelium sample
Relative Expression (log2-ratio):-5.317896Number of Samples:8 / 18
| Experimental | esophageal squamous cell carcinoma study 1 |
| Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy. | |
| Control | normal esophageal epithelium sample |
| Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy. |
rheumatoid arthritis study 31 / TNF-ɑ study 20
Relative Expression (log2-ratio):4.8668966Number of Samples:4 / 3
| Experimental | rheumatoid arthritis study 31 |
| Monocyte samples isolated from patients with rheumatoid arthritis (RA). Monocytes from whole blood were depleted from granulocytes by CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling. Patients fulfilled the revised American College of Rheumatology criteria (ACR) for RA. | |
| Control | TNF-ɑ study 20 |
| Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml TNFα in whole blood for 1.5 hour. Following stimulation, monocytes were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling. |
Barrett's esophagus study 3 / normal esophageal epithelium sample
Relative Expression (log2-ratio):-4.4593124Number of Samples:17 / 18
| Experimental | Barrett's esophagus study 3 |
| Esophageal epithelium samples from areas with Barrett's esophagus metaplasia which were recovered by laser capture microdissection. | |
| Control | normal esophageal epithelium sample |
| Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy. |
ALL study 2 (33d) / ALL study 2 (0d)
Relative Expression (log2-ratio):4.2792444Number of Samples:58 / 129
| Experimental | ALL study 2 (33d) |
| Bone marrow samples from children with de novo acute lymphoblastic leukemia. Samples were taken 33 days after remission-induction therapy (RIT). | |
| Control | ALL study 2 (0d) |
| Bone marrow samples from children with de novo acute lymphoblastic leukemia. Samples were taken before remission-induction therapy (RIT). |
ulcerative colitis study 29 (infliximab; 10mg/kg; responder; 30wk) / ulcerative colitis study 29 (infliximab; 10mg/kg; non-responder; 30wk)
Relative Expression (log2-ratio):-4.178564Number of Samples:10 / 3
| Experimental | ulcerative colitis study 29 (infliximab; 10mg/kg; responder; 30wk) |
| Colonic mucosal biopsies from ulcerative colitis patients who are responders to infliximab treatment at timepoint 30 weeks (during maintenance phase). At baseline patients had a diagnosis of moderately to severe active ulcerative colitis (Mayo score of 6 to 12). Biopsies were taken 30 weeks after patients received intravenous infusions of 10 mg infliximab per kg body weight. During induction phase (week 0-8) patients received infusions at weeks 0, 2, and 6 and during maintenance phase (weeks 8-46) patients received infusions every 8 weeks beginning at week 14. Clinical response was defined as a decrease from baseline in the total Mayo score of at least three points and at least at 30%, with an accompanying decrease in the subscore for rectal bleeding of at least one point or an absolute subscore for rectal bleeding of 0 or 1. Biopsies were collected from lesions 15 to 20 cm from the anal verge. ATC code: | |
| Control | ulcerative colitis study 29 (infliximab; 10mg/kg; non-responder; 30wk) |
| Colonic mucosal biopsies from ulcerative colitis patients who are non-responders to infliximab treatment at timepoint 30 weeks (during maintenance phase). At baseline patients had a diagnosis of moderately to severe active ulcerative colitis (Mayo score of 6 to 12). Biopsies were taken 30 weeks after patients received intravenous infusions of 10 mg infliximab per kg body weight. During induction phase (week 0-8) patients received infusions at weeks 0, 2, and 6 and during maintenance phase (weeks 8-46) patients received infusions every 8 weeks beginning at week 14. Clinical response was defined as a decrease from baseline in the total Mayo score of at least three points and at least at 30%, with an accompanying decrease in the subscore for rectal bleeding of at least one point or an absolute subscore for rectal bleeding of 0 or 1. Biopsies were collected from lesions 15 to 20 cm from the anal verge. ATC code: |
TNF-ɑ study 20 / normal monocyte sample
Relative Expression (log2-ratio):-3.938326Number of Samples:3 / 7
| Experimental | TNF-ɑ study 20 |
| Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml TNFα in whole blood for 1.5 hour. Following stimulation, monocytes were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling. | |
| Control | normal monocyte sample |
| Monocyte samples isolated from healthy subjects. Peripheral blood monocytes were isolated immediately after drawing blood by depletion from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocyte by CD14 labeling. |
MALT lymphoma study 1 / normal spleen tissue
Relative Expression (log2-ratio):-3.8543892Number of Samples:8 / 6
| Experimental | MALT lymphoma study 1 |
| Human t(11;18)-negative mucosa-associated lymphoid tissue (MALT) lymphoma cells. | |
| Control | normal spleen tissue |
| Normal human spleen tissue sample. |
ulcerative colitis study 11 / colorectal cancer study 13 (tvvad)
Relative Expression (log2-ratio):3.4787407Number of Samples:3 / 3
| Experimental | ulcerative colitis study 11 |
| Colon biopsies derived from patients with ulcerative colitis. | |
| Control | colorectal cancer study 13 (tvvad) |
| Colon biopsies derived from patients with low grade tubulovillous/villous adenoma. |
MALT lymphoma study 2 / normal spleen tissue
Relative Expression (log2-ratio):-3.4682093Number of Samples:6 / 6
| Experimental | MALT lymphoma study 2 |
| Human t(11;18)-positive mucosa-associated lymphoid tissue (MALT) lymphoma cells. | |
| Control | normal spleen tissue |
| Normal human spleen tissue sample. |